Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Pariser

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Journal of the American Academy of Dermatology|December 28, 2006
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005Lasse R Braathen, Rolf-Markus Szeimies, Nicole Basset-Seguin, et al.
Cutis|October 20, 2007
A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adultsRichard Berger, Alicia Barba, Alan Fleischer, et al.
Journal of the American Academy of Dermatology|March 7, 2025
Sofpironium topical gel, 12.45%, for the treatment of axillary hyperhidrosis: Pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studiesDavid Pariser, Dee Anna Glaser, James Del Rosso, et al.
Journal of the American Academy of Dermatology|May 7, 2013
A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasisMark G Lebwohl, Leon Kircik, Kristina Callis Duffin, et al.
Journal of the American Academy of Dermatology|November 4, 2004
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized studyCarin Gribetz, Mark Ling, Mark Lebwohl, et al.
BMC Dermatology|November 7, 2019
Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitisEric Simpson, Laurent Eckert, Abhijit Gadkari, et al.
Journal of the American Academy of Dermatology|August 3, 2021
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trialLinda Stein Gold, Kim Papp, David Pariser, et al.
The New England Journal of Medicine|November 25, 2003
A novel targeted T-cell modulator, efalizumab, for plaque psoriasisMark Lebwohl, Stephen K Tyring, Tiffani K Hamilton, et al.
Pediatric Dermatology|September 30, 2005
Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label studyDoris Staab, David Pariser, Alice B Gottlieb, et al.
Journal of Drugs in Dermatology : JDD|September 20, 2005
A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyadsHelen Torok, Susan Taylor, Leslie Baumann, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Journal of the American Academy of Dermatology|December 28, 2006
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005Lasse R Braathen, Rolf-Markus Szeimies, Nicole Basset-Seguin, et al.
Cutis|October 20, 2007
A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adultsRichard Berger, Alicia Barba, Alan Fleischer, et al.
Journal of the American Academy of Dermatology|March 7, 2025
Sofpironium topical gel, 12.45%, for the treatment of axillary hyperhidrosis: Pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studiesDavid Pariser, Dee Anna Glaser, James Del Rosso, et al.
Journal of the American Academy of Dermatology|May 7, 2013
A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasisMark G Lebwohl, Leon Kircik, Kristina Callis Duffin, et al.
Journal of the American Academy of Dermatology|November 4, 2004
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized studyCarin Gribetz, Mark Ling, Mark Lebwohl, et al.
BMC Dermatology|November 7, 2019
Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitisEric Simpson, Laurent Eckert, Abhijit Gadkari, et al.
Journal of the American Academy of Dermatology|August 3, 2021
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trialLinda Stein Gold, Kim Papp, David Pariser, et al.
The New England Journal of Medicine|November 25, 2003
A novel targeted T-cell modulator, efalizumab, for plaque psoriasisMark Lebwohl, Stephen K Tyring, Tiffani K Hamilton, et al.
Pediatric Dermatology|September 30, 2005
Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label studyDoris Staab, David Pariser, Alice B Gottlieb, et al.
Journal of Drugs in Dermatology : JDD|September 20, 2005
A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyadsHelen Torok, Susan Taylor, Leslie Baumann, et al.
Pageof 7